Last updated on April 24, 2014 at 5:15 EDT

DiagnoCure Issues Statement on Acquisition of Gen-Probe by Hologic

May 1, 2012

QUEBEC CITY, May 1, 2012 /CNW Telbec/ – DiagnoCure, Inc. (TSX: CUR), a
Quebec life sciences company that develops and commercializes
high value cancer diagnostic tests, issued a statement today commenting
on the proposed acquisition of its commercial partner Gen-Probe
(Nasdaq: GPRO) by Hologic Inc. (Nasdaq: HOLX). The acquisition,
announced yesterday, is being viewed favorably by DiagnoCure management
who see an opportunity for the combined companies to put additional
resources behind the marketing of the PROGENSA(R) PCA3 prostate cancer

“Our expectation is that the combined entity, with an expanded footprint
within cancer diagnostics, will be in an even stronger position to
bring PROGENSA PCA3 to physicians and patients” stated Dr. Yves Fradet,
President and Chief Medical Officer of DiagnoCure. “Hologic has already
demonstrated a commitment to commercializing high value tests and has
an established marketing presence in this space. Importantly, we do not
foresee any changes in the strategy to maximize the commercial
potential of PROGENSA PCA3.”

Under the terms of this transaction, announced on April 30,
Gen-Probe will become a wholly-owned subsidiary of Hologic. Hologic
intends to market Gen-Probe’s products on a global basis, focusing on
both developed and emerging markets around the world. The combined
companies will have direct sales and marketing infrastructure in the
U.S. and Europe as well as distribution capabilities in China and other
emerging markets. The Gen-Probe brand is to be maintained and it is
expected that the growth trajectory of Gen-Probe’s products will be
significantly enhanced. The transaction is expected to close in the
second half of 2012 and is subject to the satisfaction of certain
closing conditions, including approval of Gen-Probe’s shareholders.

Gen-Probe received FDA approval for the PROGENSA PCA3 assay on February
15, 2012. The urine-based test is indicated for use in conjunction with
other patient information to aid in the decision for repeat biopsy in
men 50 years of age or older who have had one or more previous negative
prostate biopsies and for whom a repeat biopsy would be recommended by
a urologist based on the current standard of care, before consideration
of PROGENSA PCA3 assay results. A negative PROGENSA PCA3 assay result
is associated with a decreased likelihood of a positive biopsy. A
prostate biopsy is required to diagnose cancer.

DiagnoCure licensed the PROGENSA PCA3 technology to Gen-Probe on an
exclusive worldwide basis in November 2003. As part of the licensing
agreement, DiagnoCure receives 8% royalties on cumulative sales up to
$62.5 million and 16% thereafter. Approximately half of the $62.5
million sales goal has been reached.

About Prostate Cancer and the PROGENSA PCA3 Assay

According to the American Cancer Society (ACS), prostate cancer is the
second most common type of cancer found in American men (behind skin
cancer), and the second-leading cause of cancer death in men (after
lung cancer). One in six American men will get prostate cancer during
his lifetime, and one in 36 will die from it. The ACS estimates that
about 241,000 Americans were newly diagnosed with prostate cancer in
2011, and that approximately 34,000 men died from the disease.

PCA3 is a gene that is highly over-expressed in prostate cancers.
Following a digital rectal examination, the PCA3 gene can be quantified
in urine specimens together with the prostate-specific antigen (PSA)
gene to generate a PCA3 score. Studies have shown that because the PCA3
gene is highly specific for prostate cancer, it predicts the results of
repeat biopsies more accurately than traditional serum PSA testing in
patients who have had one or more previous negative prostate biopsies.

Data from more than 80 peer-reviewed publications suggest that PCA3 gene
testing, when used with other patient information, may help address
some of the well-known challenges urologists face, such as identifying
prostate cancers while reducing unnecessary repeat biopsies.

Gen-Probe’s PROGENSA PCA3 assay is the first urine-based molecular
diagnostic assay to aid in the decision for repeat biopsy. The test has
received regulatory approval and is available for sale in the United
States, Canada and the European Union.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company that develops and
commercializes high-value cancer diagnostic tests that increase
clinician and patient confidence in making critical treatment
decisions. In 2008, the Company launched the Previstage(TM )GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and
granted the worldwide exclusive rights to this test to Signal Genetics
in June 2011. The Company also has a strategic alliance with Gen-Probe
(NASDAQ: GPRO) for the development and commercialization of a
second-generation prostate cancer test using PCA3, DiagnoCure’s
proprietary molecular biomarker. The PROGENSA(R) PCA3 test is
commercialized in Europe under CE mark and is now approved for
commercialization in Canada and the United States. For more
information, visit www.diagnocure.com.

Forward looking statements

This release contains forward looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forward looking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure’s control. As a result, investors are cautioned
not to place undue reliance on these forward looking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure’s
most recent Annual Information Form under the heading “Risk Factors”.
DiagnoCure undertakes no obligation to publicly update or revise any
forward looking statements contained herein unless required by the
applicable securities laws and regulations.


Source: PR Newswire